JOP20200031A1 - طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة - Google Patents

طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة

Info

Publication number
JOP20200031A1
JOP20200031A1 JOP/2020/0031A JOP20200031A JOP20200031A1 JO P20200031 A1 JOP20200031 A1 JO P20200031A1 JO P20200031 A JOP20200031 A JO P20200031A JO P20200031 A1 JOP20200031 A1 JO P20200031A1
Authority
JO
Jordan
Prior art keywords
methods
osteoarthritis
treating osteoarthritis
patient
cannabidiol
Prior art date
Application number
JOP/2020/0031A
Other languages
Arabic (ar)
English (en)
Inventor
Donna Gutterman
Griesser James
Nancy Tich
Daniel Clauw
Smith Ted
John Messenheimer
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Publication of JOP20200031A1 publication Critical patent/JOP20200031A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JOP/2020/0031A 2017-08-14 2018-08-13 طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة JOP20200031A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545468P 2017-08-14 2017-08-14
US201862661733P 2018-04-24 2018-04-24
PCT/IB2018/056090 WO2019034985A1 (en) 2017-08-14 2018-08-13 METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL

Publications (1)

Publication Number Publication Date
JOP20200031A1 true JOP20200031A1 (ar) 2020-02-12

Family

ID=65362584

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0031A JOP20200031A1 (ar) 2017-08-14 2018-08-13 طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة

Country Status (11)

Country Link
US (4) US20200170963A1 (enExample)
EP (1) EP3668500A4 (enExample)
JP (3) JP2020530857A (enExample)
KR (1) KR20200054171A (enExample)
AU (2) AU2018318425A1 (enExample)
BR (1) BR112020003025A2 (enExample)
CA (1) CA3072849A1 (enExample)
IL (2) IL301622A (enExample)
JO (1) JOP20200031A1 (enExample)
MX (1) MX2020001768A (enExample)
WO (1) WO2019034985A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7210564B2 (ja) 2017-09-28 2023-01-23 ジナーバ・ファーマシューティカルズ・インコーポレイテッド カンナビジオールによる脆弱ｘ症候群の処置
WO2020121260A1 (en) 2018-12-14 2020-06-18 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
JP2022550569A (ja) 2019-10-03 2022-12-02 スタートン セラピューティクス，インコーポレイティド ドロナビノールの経皮送達
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
JP7670700B2 (ja) 2019-10-11 2025-04-30 パイク セラピューティクス インコーポレイテッド 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US20220395572A1 (en) * 2019-10-13 2022-12-15 Figene, Llc Cannabidiol adjuvant therapy for treatment of disc degenerative disease
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CN114555068A (zh) 2019-10-14 2022-05-27 长矛治疗股份有限公司1219014 B.C.有限公司 大麻二酚的透皮给药
MX2022016536A (es) * 2020-06-29 2023-03-15 Zynerba Pharmaceuticals Inc Tratamiento del síndrome de x frágil con cannabidiol.
EP4322931A4 (en) * 2021-04-12 2025-03-12 Pike Therapeutics Inc. TRANSDERMAL DELIVERY OF CANNABIDIOL
EP4098254A1 (en) * 2021-06-04 2022-12-07 Assistance Publique, Hopitaux De Paris Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
WO2024085581A1 (ko) * 2022-10-17 2024-04-25 (주)인벤티지랩 염증성 질환의 치료 또는 예방을 위한 서방형 주사용 조성물 및 이의 제조 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
ES2396976T3 (es) * 2005-05-25 2013-03-01 Calosyn Pharma, Inc Método y composición para tratar osteoartritis
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
US9243061B2 (en) * 2008-12-22 2016-01-26 University Of Melbourne Osteoarthritis treatment
US20100273895A1 (en) * 2009-04-28 2010-10-28 Alltranz Inc. Formulations of cannabidiol and prodrugs of cannabidiol and methods of using the same
AU2009345154A1 (en) * 2009-04-29 2011-12-22 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
HRP20171236T1 (hr) * 2009-08-31 2017-10-20 Zynerba Pharmaceuticals, Inc. Upotreba prolijekova kanabidiola u topičkoj i transdermalnoj primjeni s mikroiglama
EP2864477A4 (en) * 2012-06-26 2016-02-17 Amberdale Entpr Pty Ltd ISOLATION OF STEM CELLS FROM ADIPOSE TISSUE BY ULTRASONIC CAVITATION, AND METHODS OF USE
MX2017004772A (es) * 2014-07-18 2017-10-12 Medipath Inc Composiciones y métodos para la administración fisiológica utilizando cannabidiol.

Also Published As

Publication number Publication date
WO2019034985A1 (en) 2019-02-21
EP3668500A1 (en) 2020-06-24
JP7590803B2 (ja) 2024-11-27
US20250268843A1 (en) 2025-08-28
JP2023109969A (ja) 2023-08-08
JP2020530857A (ja) 2020-10-29
BR112020003025A2 (pt) 2020-08-04
KR20200054171A (ko) 2020-05-19
US20240189255A1 (en) 2024-06-13
AU2018318425A1 (en) 2020-02-27
EP3668500A4 (en) 2021-04-28
US20240148669A1 (en) 2024-05-09
MX2020001768A (es) 2020-12-03
IL301622A (en) 2023-05-01
CA3072849A1 (en) 2019-02-21
IL272593A (en) 2020-03-31
JP2025024068A (ja) 2025-02-19
AU2024205778A1 (en) 2024-09-05
US20200170963A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
CY1123688T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20
BR112016028964A2 (pt) métodos de tratamento com antagonistas contra pd-1 e pd-l1 em combinação com terapia de radiação
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112013027010A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo para sua entrega trasdérmica, e seus usos
MX2022012001A (es) Tratamiento preventivo de la migra?a.
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
MX2021001549A (es) Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
BR112013027006A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo de distribuição transdérmica do mesmo
EA202190294A1 (ru) Комбинированная терапия для лечения рака
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca
MX2023006765A (es) Metodo para proporcionar terapia de celiprolol a un paciente.
EA202190291A1 (ru) Комбинированная терапия для лечения рака
RU2013122842A (ru) Способ лечения синдрома диабетической стопы
EA202092278A1 (ru) Римегепант для связанных с cgrp расстройств